An ear­ly ar­rival among '17 biotech IPOs, Anap­tys­Bio keeps to its range in suc­cess­ful $75M play

Anap­tys­Bio has upped its shares but still man­aged to hit the mid-point of its IPO range, rais­ing $75 mil­lion.

The suc­cess­ful out­ing marks an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.